Laboratorio Reig Jofre S.A (RJF) - Total Assets
Based on the latest financial reports, Laboratorio Reig Jofre S.A (RJF) holds total assets worth €355.15 Million EUR (≈ $415.21 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Laboratorio Reig Jofre S.A shareholders equity for net asset value and shareholders' equity analysis.
Laboratorio Reig Jofre S.A - Total Assets Trend (2004–2024)
This chart illustrates how Laboratorio Reig Jofre S.A's total assets have evolved over time, based on quarterly financial data.
Laboratorio Reig Jofre S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Laboratorio Reig Jofre S.A's total assets of €355.15 Million consist of 43.4% current assets and 56.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 3.0% |
| Accounts Receivable | €62.18 Million | 18.0% |
| Inventory | €63.77 Million | 18.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €55.28 Million | 16.0% |
| Goodwill | €26.81 Million | 7.8% |
Asset Composition Trend (2004–2024)
This chart illustrates how Laboratorio Reig Jofre S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RJF market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Laboratorio Reig Jofre S.A's current assets represent 43.4% of total assets in 2024, a decrease from 49.3% in 2004.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2024, down from 6.1% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 12.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 18.5% of total assets.
Laboratorio Reig Jofre S.A Competitors by Total Assets
Key competitors of Laboratorio Reig Jofre S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
China | CN¥1.77 Billion |
Laboratorio Reig Jofre S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 1.83 | 1.33 |
| Quick Ratio | 0.99 | 1.00 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €70.75 Million | €67.02 Million | €25.16 Million |
Laboratorio Reig Jofre S.A - Advanced Valuation Insights
This section examines the relationship between Laboratorio Reig Jofre S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.03 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | €344.85 Million |
| Market Capitalization | $221.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Laboratorio Reig Jofre S.A's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Laboratorio Reig Jofre S.A's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Laboratorio Reig Jofre S.A (2004–2024)
The table below shows the annual total assets of Laboratorio Reig Jofre S.A from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €344.85 Million ≈ $403.17 Million |
+4.33% |
| 2023-12-31 | €330.55 Million ≈ $386.45 Million |
+2.91% |
| 2022-12-31 | €321.19 Million ≈ $375.51 Million |
-1.16% |
| 2021-12-31 | €324.98 Million ≈ $379.93 Million |
+2.47% |
| 2020-12-31 | €317.15 Million ≈ $370.78 Million |
+1.13% |
| 2019-12-31 | €313.62 Million ≈ $366.65 Million |
+42.76% |
| 2018-12-31 | €219.68 Million ≈ $256.82 Million |
+8.03% |
| 2017-12-31 | €203.34 Million ≈ $237.72 Million |
-1.12% |
| 2016-12-31 | €205.63 Million ≈ $240.41 Million |
+9.93% |
| 2015-12-31 | €187.05 Million ≈ $218.69 Million |
+3.49% |
| 2014-12-31 | €180.74 Million ≈ $211.31 Million |
+106.78% |
| 2014-09-30 | €87.41 Million ≈ $102.19 Million |
+4.35% |
| 2013-12-31 | €83.77 Million ≈ $97.93 Million |
-14.58% |
| 2012-12-31 | €98.06 Million ≈ $114.64 Million |
-40.71% |
| 2011-12-31 | €165.38 Million ≈ $193.34 Million |
-9.67% |
| 2010-12-31 | €183.09 Million ≈ $214.05 Million |
-8.54% |
| 2009-12-31 | €200.18 Million ≈ $234.03 Million |
-34.90% |
| 2008-12-31 | €307.50 Million ≈ $359.50 Million |
-3.17% |
| 2007-12-31 | €317.55 Million ≈ $371.25 Million |
+9.89% |
| 2006-12-31 | €288.98 Million ≈ $337.84 Million |
+84.77% |
| 2005-12-31 | €156.40 Million ≈ $182.84 Million |
+197.13% |
| 2004-12-31 | €52.64 Million ≈ $61.54 Million |
-- |
About Laboratorio Reig Jofre S.A
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmacy, food, and animal food. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables … Read more